Voyager-V1 is under clinical development by Vyriad and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Voyager-V1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Voyager-V1 is under development for the treatment of hepatocellular carcinoma, metastatic melanoma and endometrial cancer and for relapsed and refractory hematological malignancies, solid tumors including metastatic colorectal cancer, pheochromocytoma, neuroendocrine tumor, endometrioid adenocarcinoma, non-small cell lung cancer, neuroendocrine carcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, multiple myeloma, relapsed AML, non-Hodgkin lymphoma, T-cell lymphoma such as peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, myelodysplastic syndrome, cutaneous TCL (CTCL) of mycosis fungoides (MF). The therapeutic candidate is administered by the intravenous and intratumoral route of administration. The drug candidate, vesicular stomatitis virus (VSV)-interferon beta (IFNb)-sodium iodide symporter (NIS) is an oncolytic VSV encoding IFNb and the NIS reporter. The therapeutic candidate is developed based on VSV (VSV- IFNb-NIS) technology platform. The drug candidate acts by targeting interferon beta (IFNb) and SLC5A5.
It was also under development for metastatic hepatocullular carcinoma, breast, ovarian cancer and head and neck squamous cell carcinoma.
Vyriad is a clinical stage bio-pharmaceutical company that develops viral-based novel oncolytic therapies for the treatment of cancer. The company is developing two oncolytic virus platforms such as Vesicular Stomatitis Virus (VSV) and Measles Virus (MV-NIS). It’s pipeline products include Voyager-V1 for solid tumors, MV-NIS for bladder cancer, Voyager-V1 + pembrolizumab for non-small cell lung cancer, head and neck cancer, Voyager-V1 + cemiplimab for multiple cancer indications among others. Vyriad also conducts investigator sponsored trials targeted against myeloma, endometrial cancer, multiple myeloma, T cell lymphoma medulloblastoma, and others. The company develops oncolytic virus in clinical phases of development. Vyriad is headquartered in Rochester, Minnesota, the US.
For a complete picture of Voyager-V1’s drug-specific PTSR and LoA scores, buy the report here.